2025-05-02 22:23:07
Latest Post
Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
KFin Technologies Introduces New-Gen KYC Solution to Streamline Customer Onboarding
Meson Valves India Ltd receives order worth approx Rs. 12.50 crore
Oriental Rail Infrastructure Ltd receives order worth Rs. 2.46 crore
Punjab Chemicals & Crop Protection Ltd recommends dividend of Rs. 3
Stock Report
Sandu Pharmaceuticals Ltd posts PAT of Rs. 0.2933 crore in Q3FY21
Posted On : 2021-02-14 14:34:14( TIMEZONE : IST )
SANDU PHARMACEUTICALS LTD. has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.15.84 crores during the period ended December 31, 2020 as compared to Rs.17.28 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.0.2933 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.0.3967 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.0.41 for the period ended December 31, 2020 as compared to Rs.0.56 for the period ended September 30, 2020.
| Financials | Q3 FY20-21 | Q2 FY20-21 | % Change |
| Total Income | ₹ 15.84 crs | ₹ 17.28 crs |  -8.33% |
| Net Profit | ₹ 0.2933 crs | ₹ 0.3967 crs | -26.07% |
| EPS | ₹ 0.41 | ₹ 0.56 | -26.79% |
Financial Results (Q3 FY20-21) - YoY Comparison
The company has reported total income of Rs.15.84 crores during the period ended December 31, 2020 as compared to Rs.13.31 crores during the period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.0.2933 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.0.1563 crores for the period ended December 31, 2019.
The company has reported EPS of Rs.0.41 for the period ended December 31, 2020 as compared to Rs.0.22 for the period ended December 31, 2019.
| Financials | Q3 FY20-21 | Q3 FY19-20 | % Change |
| Total Income | ₹ 15.84 crs | ₹ 13.31 crs |  19.01% |
| Net Profit | ₹ 0.2933 crs | ₹ 0.1563 crs | 87.65% |
| EPS | ₹ 0.41 | ₹ 0.22 | 86.36% |
Financial Results (9 Months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.44.82 crores during the 9 months period ended December 31, 2020 as compared to Rs.37.76 crores during the 9 months period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.0.7280 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.0.6989 crores for the 9 months period ended December 31, 2019.
The company has reported EPS of Rs.1.03 for the 9 months period ended December 31, 2020 as compared to Rs.0.99 for the 9 months period ended December 31, 2019.
| Financials | 9 Months ended FY20-21 | 9 Months ended FY19-20 | % Change |
| Total Income | ₹ 44.82 crs | ₹ 37.76 crs | 18.7% |
| Net Profit | ₹ 0.7280 crs | ₹ 0.6989 crs | 4.16% |
| EPS | ₹ 1.03 | ₹0.99 | 4.04% |
Shares of SANDU PHARMACEUTICALS LTD. was last trading in BSE at Rs.30.15 as compared to the previous close of Rs. 30.65. The total number of shares traded during the day was 138 in over 3 trades.
The stock hit an intraday high of Rs. 30.15 and intraday low of 30.15. The net turnover during the day was Rs. 4160.
